Noom has launched a new Proactive Health GLP-1 Program focused on preventive health care. The program includes at-home testing of 17 biomarkers, behavioral support, and personalized GLP-1 microdosing ...

The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D and Medicaid plans, but experts say it's unclear how ...

Summer Kessel is a Registered Dietitian and Certified Specialist in Obesity and Weight Management. She is currently serving as cofounder and chief of operations, Community & Nutrition at Vineyard, a ...

Early signs show popular weight loss drugs may curb more than just food cravings. GLP-1’s like Ozempic, Mounjaro may also help patients with addiction. New Budweiser Super Bowl ad What time should you ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Calocurb is a natural, prescription-free supplement designed to suppress appetite and reduce calorie intake. The supplement works by naturally supporting GLP-1 activation using an extract from New ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. January has a funny way of making us ambitious.

With GLP-1 use rising across the country, major brands are boosting protein, cutting sugar, and reworking formulations and packaging to fit how shoppers are eating today. Stacey Leasca is an ...

Certain dietary supplements like protein powder, calcium, and fiber may enhance GLP-1 secretion, which plays a role in insulin production and appetite regulation. While these supplements can be more ...

The popularity of GLP-1 weight-loss drugs has seen a seismic shift in just over a year. Not long ago, they were primarily used for diabetes. But now, that’s changing. In some markets, such as the US, ...

Long-term adherence to GLP-1 obesity drugs is low, but 2024 data shows improvement, indicating evolving treatment understanding. Payers are exploring policy options to address the cost-effectiveness ...